{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=14", "query": { "intervention": "Anti-tumor B", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 665, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:05:00.924Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03872778", "title": "[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "[177Lu]-NeoB", "type": "DRUG" }, { "name": "[68Ga]-NeoB", "type": "DRUG" }, { "name": "LCZ696", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-07-24", "completion_date": "2025-11-27", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Baltimore, Maryland + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872778" }, { "nct_id": "NCT03436563", "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "High-Frequency Microsatellite Instability", "Metastatic Malignant Solid Neoplasm", "Rectal Adenocarcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-03-07", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436563" }, { "nct_id": "NCT03019055", "title": "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" }, { "name": "CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 26, "start_date": "2017-10-16", "completion_date": "2021-08-24", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019055" }, { "nct_id": "NCT02215967", "title": "Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma, Plasma-Cell", "Myeloma-Multiple" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "73 Years", "sex": "ALL", "summary": "18 Years to 73 Years" }, "enrollment_count": 30, "start_date": "2014-08-12", "completion_date": "2019-08-15", "has_results": true, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02215967" }, { "nct_id": "NCT05450692", "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 594, "start_date": "2022-09-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 27, "location_summary": "Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450692" }, { "nct_id": "NCT02302807", "title": "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 931, "start_date": "2015-01-13", "completion_date": "2018-11-08", "has_results": true, "last_update_posted_date": "2019-08-01", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302807" }, { "nct_id": "NCT04616248", "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Unresectable Breast Carcinoma", "Metastatic Melanoma", "Unresectable Melanoma", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Soft Tissue Sarcoma", "Bone Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma of Bone", "Basal Cell Carcinoma" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-09", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616248" }, { "nct_id": "NCT01983761", "title": "Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blood And Marrow Transplantation", "Leukemia", "Lymphoma", "Transplantation Infection", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin's Lymphoma (NHL)", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)", "type": "DRUG" }, { "name": "Fludarabine, Melphalan, ATG (Reduced Intensity)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Targazyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 25, "start_date": "2013-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-18", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 4, "location_summary": "La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01983761" }, { "nct_id": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Sonesitatug Vedotin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "FLOT Chemotherapy", "type": "DRUG" }, { "name": "Calcium folinate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-07-17", "completion_date": "2029-07-16", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 7, "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "North Shores", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07069712" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-15T04:05:00.924Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" } ] }